Latest version of ClearTrial software expands ability of life sciences organizations to accelerate the planning, execution, and outsourcing of clinical trials.
Chicago, IL-May 8, 2008-ClearTrial (www.cleartrial.com), a leading provider of clinical trial software for clinical operations planning, budgeting, and outsourcing, announced today that it has released v2.4 of its market-leading ClearTrial clinical trial software, which helps biopharmaceutical companies and clinical research organizations (CROs) more effectively plan, budget, outsource, and optimize the operational design of clinical trials. Officially unveiled at the 2008 Partnerships with CROs conference, v2.4 of the ClearTrial software is now used by some of the largest biopharma organizations in the industry and by five of the top 10 biotech companies.
For the past several years, ClearTrial’s customers in clinical operations, outsourcing, finance, and project management have been drawing on the web-based software’s innovative, easy-to-use design to apply a true activity-based planning approach to:
The latest version of the software provides customers with even greater control and flexibility over their clinical operations planning. Among the key enhancements in ClearTrial v2.4 are support for mixed-monitoring strategies, a customizable milestone payment schedule and cash flow chart for an accurate cash flow status for each month of the study, greater flexibility to set resources and rate per-plan or per-task, and the ability for upload service provider rates into the software.
In addition, v2.4 broadens the already considerable array of clinical, cost, and resources reports available in the software, adding “Resources by Major Task” and “Resources by Department” reports to give planners a detailed and customizable look at resources-and enhancing support for resource forecasting and negotiating how studies will be staffed.
“ClearTrial software continues to lead the market in giving life sciences organizations the planning speed, flexibility, and consistency they need in today’s demanding clinical development environment,” noted Michael Soenen, managing partner of ClearTrial. “Our customers are saving time and money on their clinical studies, while maintaining the quality of their study results. And new customers are amazed by the minimal startup effort, since they can become fully operational on the software in just a few days.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.